{"id":63222,"date":"2026-04-15T21:27:54","date_gmt":"2026-04-15T13:27:54","guid":{"rendered":"https:\/\/flcube.com\/?p=63222"},"modified":"2026-04-15T21:27:56","modified_gmt":"2026-04-15T13:27:56","slug":"eli-lilly-to-acquire-crossbridge-bio-for-up-to-300-million-to-bolster-adc-pipeline-with-novel-trop2-targeting-candidate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63222","title":{"rendered":"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced plans to acquire <strong>CrossBridge Bio<\/strong>, a Houston-based biotechnology company specializing in <strong>antibody drug conjugate (ADC)<\/strong> development, for up to <strong>USD 300 million<\/strong>. The acquisition centers on <strong>CBB-120<\/strong>, CrossBridge&#8217;s lead asset featuring an innovative <strong>dual-payload approach<\/strong> targeting <strong>TROP2<\/strong> for cancer treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly and Company (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>CrossBridge Bio (Houston, TX)<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>Up to USD 300 million<\/td><\/tr><tr><td><strong>Target Founded<\/strong><\/td><td>2023<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>CBB-120 (TROP2-targeting ADC)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Pre-IND; IND submission expected in 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profile-cbb-120\">Asset Profile \u2013 CBB-120<\/h2>\n\n\n\n<p><strong>CBB-120<\/strong> represents a next-generation <strong>TROP2-targeting antibody drug conjugate<\/strong> with a differentiated dual-payload design:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: TROP2 (trophoblast cell-surface antigen 2) \u2013 overexpressed in multiple solid tumors<\/li>\n\n\n\n<li><strong>Dual Payload<\/strong>:<\/li>\n\n\n\n<li><strong>TOP1i<\/strong> (topoisomerase I inhibitor)<\/li>\n\n\n\n<li><strong>ATRi<\/strong> (ATR kinase inhibitor)<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Designed to improve <strong>therapeutic index<\/strong> and achieve <strong>more durable efficacy<\/strong> compared to current TROP2 ADCs<\/li>\n\n\n\n<li><strong>Resistance Strategy<\/strong>: Addresses key resistance mechanisms that limit current single-payload ADC approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Portfolio Expansion<\/strong>: Strengthens Lilly&#8217;s position in the rapidly evolving ADC space following recent oncology-focused acquisitions<\/li>\n\n\n\n<li><strong>Innovation Premium<\/strong>: Dual-payload technology represents cutting-edge ADC design aimed at overcoming limitations of current generation agents<\/li>\n\n\n\n<li><strong>TROP2 Market Opportunity<\/strong>: TROP2 is emerging as a high-value target across multiple tumor types including breast, lung, and bladder cancers<\/li>\n\n\n\n<li><strong>Early-Stage Optionality<\/strong>: Acquisition of a 2023-founded company provides cost-effective access to novel technology with significant upside potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-analysis\">Competitive Landscape Analysis<\/h2>\n\n\n\n<p>The <strong>TROP2 ADC market<\/strong> has seen intense competition following the success of drugs like Enhertu and Trodelvy. Key differentiating factors for CBB-120 include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Mechanism<\/strong>: Simultaneous DNA damage (TOP1i) and DNA repair inhibition (ATRi) creates synthetic lethality<\/li>\n\n\n\n<li><strong>Therapeutic Index<\/strong>: Improved safety profile could enable higher dosing and better efficacy<\/li>\n\n\n\n<li><strong>Resistance Management<\/strong>: Dual payloads may prevent or delay emergence of resistance mechanisms common with single-agent ADCs<\/li>\n\n\n\n<li><strong>Platform Potential<\/strong>: Technology could be applied to other tumor-associated antigens beyond TROP2<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-implications\">Industry Implications<\/h2>\n\n\n\n<p>Lilly&#8217;s acquisition reflects the broader pharmaceutical industry trend of securing <strong>next-generation ADC technologies<\/strong> through strategic M&amp;A. The dual-payload approach represents an evolution beyond traditional single-payload ADCs, potentially offering superior clinical outcomes in difficult-to-treat cancers.<\/p>\n\n\n\n<p>The deal also highlights the <strong>premium placed on early-stage innovation<\/strong>, with a three-year-old biotech commanding up to $300 million based on preclinical data and platform potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-outlook\">Forward Outlook<\/h2>\n\n\n\n<p>With an <strong>IND submission expected in 2026<\/strong>, CBB-120 could enter clinical trials later this year, positioning Lilly to potentially advance a differentiated TROP2 ADC into late-stage development within the next 2-3 years.<\/p>\n\n\n\n<p>The acquisition complements Lilly&#8217;s existing oncology portfolio and reinforces the company&#8217;s commitment to innovative cancer therapeutics through both internal development and external partnerships.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition completion, clinical development timelines, regulatory submissions, and market opportunities for CBB-120. Actual results may differ due to risks including transaction closing conditions, IND acceptance, clinical trial outcomes, and competitive dynamics in the ADC market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,4691,199,911],"class_list":["post-63222","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-crossbridge-bio","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology company specializing in antibody drug conjugate (ADC) development, for up to USD 300 million. The acquisition centers on CBB-120, CrossBridge&#039;s lead asset featuring an innovative dual-payload approach targeting TROP2 for cancer treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63222\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology company specializing in antibody drug conjugate (ADC) development, for up to USD 300 million. The acquisition centers on CBB-120, CrossBridge&#039;s lead asset featuring an innovative dual-payload approach targeting TROP2 for cancer treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63222\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T13:27:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T13:27:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63222#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63222\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate\",\"datePublished\":\"2026-04-15T13:27:54+00:00\",\"dateModified\":\"2026-04-15T13:27:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63222\"},\"wordCount\":492,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"CrossBridge Bio\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63222#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63222\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63222\",\"name\":\"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T13:27:54+00:00\",\"dateModified\":\"2026-04-15T13:27:56+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology company specializing in antibody drug conjugate (ADC) development, for up to USD 300 million. The acquisition centers on CBB-120, CrossBridge's lead asset featuring an innovative dual-payload approach targeting TROP2 for cancer treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63222#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63222\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63222#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology company specializing in antibody drug conjugate (ADC) development, for up to USD 300 million. The acquisition centers on CBB-120, CrossBridge's lead asset featuring an innovative dual-payload approach targeting TROP2 for cancer treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63222","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate","og_description":"Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology company specializing in antibody drug conjugate (ADC) development, for up to USD 300 million. The acquisition centers on CBB-120, CrossBridge's lead asset featuring an innovative dual-payload approach targeting TROP2 for cancer treatment.","og_url":"https:\/\/flcube.com\/?p=63222","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T13:27:54+00:00","article_modified_time":"2026-04-15T13:27:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63222#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63222"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate","datePublished":"2026-04-15T13:27:54+00:00","dateModified":"2026-04-15T13:27:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63222"},"wordCount":492,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","CrossBridge Bio","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63222#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63222","url":"https:\/\/flcube.com\/?p=63222","name":"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T13:27:54+00:00","dateModified":"2026-04-15T13:27:56+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology company specializing in antibody drug conjugate (ADC) development, for up to USD 300 million. The acquisition centers on CBB-120, CrossBridge's lead asset featuring an innovative dual-payload approach targeting TROP2 for cancer treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63222#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63222"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63222#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63222"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63222\/revisions"}],"predecessor-version":[{"id":63224,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63222\/revisions\/63224"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}